e-learning
resources
Vienna 2012
Monday, 03.09.2012
Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis
F. Bonella, X. He, S. Ohshimo, J. Guzman, U. Costabel (Essen, Bochum, Germany; Hiroshima, Japan)
Source:
Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Session:
Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Session type:
Poster Discussion
Number:
1768
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Bonella, X. He, S. Ohshimo, J. Guzman, U. Costabel (Essen, Bochum, Germany; Hiroshima, Japan). Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis. Eur Respir J 2012; 40: Suppl. 56, 1768
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis
Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases
Year: 2009
Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage
Source: International Congress 2016 – Orphan diseases I
Year: 2016
MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis
Source: Eur Respir J, 49 (5) 1700178; 10.1183/13993003.00178-2017
Year: 2017
Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis
Source: Eur Respir J, 49 (5) 1700407; 10.1183/13993003.00407-2017
Year: 2017
KL-6 in whole lung lavage fluid of patients with pulmonary alveolar proteinosis
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009
Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis
Source: Eur Respir J 2012; 39: 777-780
Year: 2012
Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009
Pulmonary alveolar proteinosis
Source: Respipedia Article
Year: 2017
Difference in the dynamic state between SP-A and SP-D in the IPF lung
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Our cases with pulmonary alveolar proteinosis
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
Serum and BALF levels of YKL-40 in patients with alveolar proteinosis
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
The role of apoptosis in idiopathic pulmonary alveolar proteinosis
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006
Lung function and symptom improvement in patients with pulmonary alveolar proteinosis after whole lung lavage or N-acetylcysteine treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 83s
Year: 2005
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease
Source: Annual Congress 2011 - COPD: human studies
Year: 2011
Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Differences in the immunolocalization of surfactant protein (SP)-A, SP-D and KL-6 in pulmonary alveolar proteinosis
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept